---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-038108"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2024-09-25T23:59:59+00:00"
generated_at: "2026-05-31T01:48:49.354205+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# RenovoRx increases RenovoCath production, expands Medical Murray partnership with warrant for 709,500 shares

## Summary
- RenovoRx boosts production of FDA-cleared RenovoCath catheter due to strong physician demand; over 500 procedures performed.
- New work order with Medical Murray; RenovoRx issues warrant for up to 709,500 shares to incentivize manufacturing milestones.
- Phase III TIGeR-PaC trial in pancreatic cancer continues; 52nd event (interim analysis) expected late 2024 or early 2025.
- CEO expects commercial launch of RenovoCath as standalone device to generate revenue during 2025; sufficient cash on hand.
- Robert Strasser promoted to VP of R&D and Operations to lead manufacturing and commercial strategy.

## SEC filing metadata
- accession: 0001493152-24-038108
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2024-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315224038108/0001493152-24-038108-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315224038108/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-038108
- JSON: https://secwatch.observer/filing/0001493152-24-038108.json
- Plain text: https://secwatch.observer/filing/0001493152-24-038108.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.